A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Brief description of study

This is a multicenter, multicountry, open-label, Phase 1b study for dose finding as well as parallel cohort dose expansion(s) to determine the recommended dose and regimen of durvalumab either as monotherapy or in combination with pomalidomide (POM) with or without low dose dex in subjects with Relapsed and Refractory Multiple Myeloma (RRMM). The study will consist of a dose-finding portion as well as a parallel dose expansion portion to determine the optimal dose and regimen.

Clinical Study Identifier: NCT02616640

Detailed Study Description

This is a multicenter, multicountry, open-label, Phase 1b study for dose finding as well as parallel cohort dose expansion(s) to determine the recommended dose and regimen of durvalumab either as monotherapy or in combination with pomalidomide (POM) with or without low dose dex in subjects with Relapsed and Refractory Multiple Myeloma (RRMM). The study will consist of a dose-finding portion as well as a parallel dose expansion portion to determine the optimal dose and regimen.

Contact research investigator to learn more about this study by filling out the form below.


To: Research Study Investigator
Subject: I am interested in participating in your Research Study
Dear Investigator,
I'm interested in learning more about and participating in your research study named: A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Included below is some of my health information:
  1. Condition = Multiple Myeloma
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.